Miles Capital Inc. decreased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 33.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,898 shares of the biotechnology company’s stock after selling 934 shares during the period. Miles Capital Inc.’s holdings in United Therapeutics Corporation were worth $257,000 as of its most recent filing with the SEC.
Other institutional investors have also recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 73 shares in the last quarter. Focused Wealth Management Inc purchased a new stake in shares of United Therapeutics Corporation during the fourth quarter valued at about $115,000. Advisory Services Network LLC purchased a new stake in shares of United Therapeutics Corporation during the first quarter valued at about $147,000. Daiwa Securities Group Inc. raised its position in United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 200 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new position in United Therapeutics Corporation during the first quarter valued at $204,000.
United Therapeutics Corporation (NASDAQ UTHR) traded down 0.36% during midday trading on Tuesday, reaching $130.12. The company’s stock had a trading volume of 348,088 shares. United Therapeutics Corporation has a 52 week low of $97.52 and a 52 week high of $169.89. The firm has a 50 day moving average price of $124.48 and a 200-day moving average price of $138.58. The firm has a market cap of $5.86 billion, a P/E ratio of 9.14 and a beta of 1.56.
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, topping the Zacks’ consensus estimate of $3.12 by $0.77. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The business had revenue of $370.50 million during the quarter, compared to analysts’ expectations of $399.59 million. During the same quarter in the previous year, the company earned $3.02 EPS. The business’s quarterly revenue was up .4% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post $14.42 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/06/20/miles-capital-inc-sells-934-shares-of-united-therapeutics-corporation-uthr-updated.html.
UTHR has been the topic of several recent research reports. J P Morgan Chase & Co set a $125.00 target price on United Therapeutics Corporation and gave the company a “hold” rating in a report on Tuesday, April 11th. Oppenheimer Holdings, Inc. set a $175.00 price target on United Therapeutics Corporation and gave the company a “buy” rating in a research report on Wednesday, February 22nd. Cowen and Company downgraded United Therapeutics Corporation from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $140.00 to $121.00 in a research report on Monday, April 3rd. Wedbush reissued an “outperform” rating and set a $229.00 target price on shares of United Therapeutics Corporation in a research report on Tuesday, April 4th. Finally, BidaskClub raised United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research report on Friday. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. United Therapeutics Corporation presently has a consensus rating of “Hold” and an average price target of $137.09.
In other news, Director Tommy G. Thompson sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 22nd. The shares were sold at an average price of $139.37, for a total value of $278,740.00. Following the completion of the sale, the director now owns 2,000 shares of the company’s stock, valued at approximately $278,740. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,238 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $130.20, for a total transaction of $161,187.60. Following the completion of the sale, the chief executive officer now directly owns 1,378 shares of the company’s stock, valued at approximately $179,415.60. The disclosure for this sale can be found here. In the last three months, insiders sold 18,258 shares of company stock valued at $2,315,560. Corporate insiders own 7.50% of the company’s stock.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.